Lista de obras -

Analysis of genotype 1b hepatitis C virus IRES in serum and peripheral blood mononuclear cells in patients treated with interferon and ribavirin

artículo científico publicado en 2014

Better outcome of HBe Ag (-) than HBe Ag (+) lamivudine treatment of HBV chronically infected patients.

artículo científico publicado en 2010

Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection

artículo científico publicado en 2020

Comparison of 5'UTR and HVR1 of hepatitis c virus (HCV) in serum and peripheral blood mononuclear cells in the early phase of interferon and ribavirin treatment

artículo científico publicado en 2011

Comparison of early virologic response among patients with chronic hepatitis C infected with genotype non 2/3 treated with pegylated interferon alfa-2B and ribavirin in dependence with hepatic fibrosis stages

artículo científico publicado en 2006

Corrigendum: Next-generation Sequencing Analysis of New Genotypes Appearing During Antiviral Treatment of Chronic Hepatitis C Reveals that These Are Selected from Pre-existing Minor Strains

scientific article published on 11 January 2019

Decrease of T-cells exhaustion markers programmed cell death-1 and T-cell immunoglobulin and mucin domain-containing protein 3 and plasma IL-10 levels after successful treatment of chronic hepatitis C

artículo científico publicado en 2020

Deep sequencing of hepatitis C virus hypervariable region 1 reveals no correlation between genetic heterogeneity and antiviral treatment outcome

artículo científico publicado en 2014

Distribution of HCV genotypes in Poland

artículo científico publicado en 2013

Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study.

artículo científico publicado en 2015

Effect of comedication on ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy in chronic hepatitis C - a real-world study

artículo científico publicado en 2019

Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics

artículo científico publicado en 2021

Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study.

artículo científico publicado en 2017

Efficacy of HCV treatment in Poland at the turn of the interferon era - the EpiTer study

artículo científico publicado en 2016

Expression of programmed cell death protein 1 and T-cell immunoglobulin- and mucin-domain-containing molecule-3 on peripheral blood CD4+CD8+ double positive T cells in patients with chronic hepatitis C virus infection and in subjects who spontaneous

artículo científico publicado en 2019

Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study

artículo científico publicado en 2021

HCV Genotype Has No Influence on the Incidence of Diabetes—EpiTer Multicentre Study

artículo científico publicado en 2022

Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study

artículo científico publicado en 2022

Hepatitis C virus (HCV) genotype 1b displays higher genetic variability of hypervariable region 1 (HVR1) than genotype 3

scientific article published on 06 September 2019

Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals?

artículo científico publicado en 2018

Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all HCV infected patients in the real-world experience?

artículo científico publicado en 2020

Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA

artículo científico publicado en 2020

Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection

artículo científico publicado en 2022

Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.

artículo científico publicado en 2014

Pegylated interferon-alfa 2a with ribavirin in chronic viral hepatitis C (final report)

artículo científico publicado en 2005

Prevalence of HCV genotypes in Poland - the EpiTer study

artículo científico publicado en 2016

Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.

artículo científico publicado en 2014

Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.

artículo científico publicado en 2019

Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients

artículo científico publicado en 2012

Study of the efficacy of combined therapy with interferon alfacon-1 and ribavirin for chronic hepatitis C

artículo científico publicado en 2006

The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study

scholarly article by Ewa Janczewska et al published 16 November 2018 in BMC Infectious Diseases

Ultradeep pyrosequencing of hepatitis C virus hypervariable region 1 in quasispecies analysis

artículo científico publicado en 2013

[Results of 48 weeks lamivudine treatment of patients with chronic hepatitis B and HBeAg (+)]

scientific article published on 01 January 2006

[Results of 48 weeks lamivudine treatment of patients with chronic hepatitis B and HBeAg (-)].

artículo científico publicado en 2006

Lista de obras de

Analysis of genotype 1b hepatitis C virus IRES in serum and peripheral blood mononuclear cells in patients treated with interferon and ribavirin

Better outcome of HBe Ag (-) than HBe Ag (+) lamivudine treatment of HBV chronically infected patients.

Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection

Comparison of 5'UTR and HVR1 of hepatitis c virus (HCV) in serum and peripheral blood mononuclear cells in the early phase of interferon and ribavirin treatment

Comparison of early virologic response among patients with chronic hepatitis C infected with genotype non 2/3 treated with pegylated interferon alfa-2B and ribavirin in dependence with hepatic fibrosis stages

Corrigendum: Next-generation Sequencing Analysis of New Genotypes Appearing During Antiviral Treatment of Chronic Hepatitis C Reveals that These Are Selected from Pre-existing Minor Strains

Decrease of T-cells exhaustion markers programmed cell death-1 and T-cell immunoglobulin and mucin domain-containing protein 3 and plasma IL-10 levels after successful treatment of chronic hepatitis C

Deep sequencing of hepatitis C virus hypervariable region 1 reveals no correlation between genetic heterogeneity and antiviral treatment outcome

Distribution of HCV genotypes in Poland

Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study.

Effect of comedication on ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy in chronic hepatitis C - a real-world study

Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics

Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study.

Efficacy of HCV treatment in Poland at the turn of the interferon era - the EpiTer study

Expression of programmed cell death protein 1 and T-cell immunoglobulin- and mucin-domain-containing molecule-3 on peripheral blood CD4+CD8+ double positive T cells in patients with chronic hepatitis C virus infection and in subjects who spontaneous

Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study

HCV Genotype Has No Influence on the Incidence of Diabetes—EpiTer Multicentre Study

Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study

Hepatitis C virus (HCV) genotype 1b displays higher genetic variability of hypervariable region 1 (HVR1) than genotype 3

Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals?

Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all HCV infected patients in the real-world experience?

Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA

Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection

Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.

Pegylated interferon-alfa 2a with ribavirin in chronic viral hepatitis C (final report)

Prevalence of HCV genotypes in Poland - the EpiTer study

Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.

Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.

Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients

Study of the efficacy of combined therapy with interferon alfacon-1 and ribavirin for chronic hepatitis C

The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study

Ultradeep pyrosequencing of hepatitis C virus hypervariable region 1 in quasispecies analysis

[Results of 48 weeks lamivudine treatment of patients with chronic hepatitis B and HBeAg (+)]

[Results of 48 weeks lamivudine treatment of patients with chronic hepatitis B and HBeAg (-)].